FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Topical Steroid

Therapeutic area intelligence for Topical Steroid with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Aurobindo Pharma →

Assets

Aurobindo →

Organon →

Recent signals(2)

RegulatoryAugust 15, 2026

Aurobindo Pharma's Triamcinolone Acetonide ANDA220110 Receives AP Status

Aurobindo Pharma Ltd. has received Abbreviated Approval (AP) for its ANDA220110 application for Triamcinolone Acetonide, a topical steroid indicated for dermatological conditions. This approval allows Aurobindo to enter the dermatology market, where it will compete with existing generic products.

RegulatoryJuly 9, 2026

FDA Accepts Supplement Application for ELOCON (Mometasone Furoate)

The FDA has accepted a supplemental application for ELOCON, a topical steroid containing mometasone furoate, submitted by Organon.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.